Evidence map›Paper›PMID 34853754›Full record

ReviewCureus2021

Role of Gastrointestinal Dysbiosis and Fecal Transplantation in Parkinson's Disease.

Rahul Jena, Ruchi Jain, Suchitra Muralidharan, Vijaya Lakshmi Yanamala, Zainab Zubair, Ketan Kantamaneni, Krishi Jalla, Mahvish Renzu, Michael Alfonso

Open access · diamondAbstract readReview
In one paragraph

Review in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Rahul JenaInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Ruchi JainDiagnostic Radiology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Suchitra MuralidharanInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Vijaya Lakshmi YanamalaSurgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Zainab ZubairGeneral Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Ketan KantamaneniSurgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Krishi JallaInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Mahvish RenzuInternal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Michael AlfonsoSchool of Medicine, Universidad del Rosario, Bogota, COL.
Siddhartha Medical College · INUniversidad del Rosario · COCalifornia Institute of Behavioral Neurosciences and Psychology (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases with a high rate of morbidity. It is associated with dopaminergic neuron loss and is fairly common in the elderly population. Recently, there has been a growing interest in the role of the gut microbiome in the pathogenesis of PD and thus studies addressing the methods to modulate the microbiota are becoming increasingly popular. Fecal microbiota transplant (FMT) is one of these methods and is effective in certain intestinal and extraintestinal conditions. This review aims to talk about gastrointestinal dysbiosis and how the reconstruction of this microbiome via FMT could potentially be used as a treatment modality in the future. We went through various studies and collected data relevant to our topic from the previous five years. The studies selected include reviews, observational studies, animal studies, case reports, and some grey literature. We concluded that although it has great potential as a therapeutic modality in the future, it is limited by several factors such as variability among the results of most clinical studies and the lack of large sample sizes. Therefore, there is a need for high-quality clinical trials with larger sample sizes to gather enough clinical evidence so that FMT can qualify as a widely recommended therapeutic measure.

Indexed as

fecal microbiotagastrointestinal microbiomegut dysbiosisneurodegenerationparkinson' s diseasetransplant

Identifiers

PMID34853754
PMCPMC8608042
OpenAlexW3209446462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.